

IFW

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Lisonbee et al.

Serial No.: 10/663,353

Filed: September 15, 2003

For: COMPOSITIONS INCLUDING DIFFERENT TYPES OF TRANSFER FACTOR, METHODS FOR MAKING THE COMPOSITIONS, AND METHODS OF TREATMENT USING THE

COMPOSITIONS

Confirmation No.: 1601

Examiner: Unknown

Group Art Unit: 1614

Attorney Docket No.: 2820-5964US

NOTICE OF EXPRESS MAILING

Express Mail Mailing Label Number: EV348043480US

Date of Deposit with USPS: __June 10, 2004

Person making Deposit: Christopher Haughton

REQUEST FOR RECONSIDERATION OF PETITION TO MAKE SPECIAL (INFRINGEMENT)

Mail Stop Petition Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Attention: Special Program Examiner for Relevant Group Art Unit (1614)

Petition

A Petition to Make Special was filed pursuant to M.P.E.P. § 708.02 II on February 26, 2004.

Requirements under M.P.E.P. § 708.02 II

€,

- (A) There is an infringing service actually on the market and an infringing method actually in use.
- (B) A rigid comparison of the alleged infringing service and method with the claims of the above-referenced application has been made. In the opinion of the undersigned attorney, some of the claims are unquestionably infringed.
- (C) The undersigned attorney has made a careful and thorough search of the prior art.

The Petition was dismissed in a Decision dated May 4, 2004, for failing to comply with the requirement that a careful and thorough search of the prior art be conducted. It is respectfully submitted that such a search was conducted and did not result in the discovery of any art that would be material to the patentability of the subject matter recited in the claims of the above-referenced application.

In any event, another thorough search has been conducted, and the references that are most relevant to the patentability of the claims of the above-referenced application are being cited in an Information Disclosure Statement that is being filed concurrently herewith.

In addition, the Office has demanded that "some evidence of an allegedly infringing product[,] identified by name, trademark, etc., . . . be presented . . ."

Copies of marketing literature for IMMUNE TRANSFER CTM, a product of ProHealth, Inc., are enclosed. Specifically, the ProHealth marketing literature indicates that "ImmuneTransfer CTM is a scientifically formulated blend of transfer factors derived from chicken lymphocytes and colostrum extracts . . .," subject matter which falls within the scopes of the claims of the above-referenced application. Based upon information and belief, it is our understanding that this literature was not published until after the filing date of the above-referenced application.

Fee

A check in the amount of \$130.00 was filed with the Petition to Make Special of February 26, 2004 to satisfy the fee required by 37 C.F.R. § 1.17(h). In the event that there is any

deficiency in the fee, or if an overpayment has been made, the Office is hereby authorized to debit or credit TraskBritt Deposit Account No. 20-1469 for any such deficiency or overpayment.

Prompt reconsideration of the Petition to Make Special is respectfully requested.

Respectfully submitted,

Brick G. Power

Registration No. 38,581 Attorney for Applicants

TRASKBRITT, PC

P.O. Box 2550

Salt Lake City, Utah 84110-2550

Telephone: 801-532-1922

Date: June 10, 2004

Enclosures: Copy of Decision on Petition to Make Special (Infringement)

Copy of Information Disclosure Statement and References

Copy of "Transfer Factor—The Key to Immune System Memory"

Copy of "Immune Transfer C TM - Complex transfer factor for fatigue and

more," from www.immunesupport.com on January 22, 2004

BGP/rmh
Document in ProLaw





RECEIVED MAY 1 0 2004

TRASKBRITT BC

COMMISSIONER FOR PATENTS UNITED STATES PATENT AND TRADEMARK OFFICE P.O. Box 1450 ALEXANDRIA, VA 22313-1450 www.uspto.gov

MAY - 4 2004

TRASK BRITT

P.O. BOX 2550 SALT LAKE CITY UT 84110

In re Application of David Lisonbee et al

Serial No.: 10/663,353 Filed: September 15, 2003

Attorney Docket No.: 2820-5964

: PETITION TO MAKE SPECIAL

This is in response to applicants' petition filed February 26, 2004, to make the above-identified application special under the provisions of 37 CFR 1.102(d).

Applicant has not satisfied the provisions set forth in M.P.E.P. 708.02, II, relating to actual or potential infringement. Therefor the petition is **DISMISSED**.

Applicants' petition indicates the "making of a careful and thorough search" and that "all of the references...located...are already of record...in the application. Accordingly no additional references are supplied." However, no references are of record in the application and no listing of references was supplied. One or two US Patents are noted in the specification, however this does not satisfy the requirement set forth in M.P.E.P. 708.02, II. Some indication of the area searched and a listing of references discovered which are most closely related to the claimed subject matter is required.

In addition, some evidence of an allegedly infringing product identified by name, trademark, etc., should be presented where it is alleged that a product is infringed.

Should there be any questions with regard to this letter please contact William R. Dixon, Jr. by letter addressed to the Director, Technology Center 1600, P.O. Box 1450, Alexandria, VA 22313-1450, or by telephone at 571-272-0519 or by facsimile transmission to the Office general facsimile number.

William R. Dixon, Ir. Special Program Examiner

Technology Center 1600

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Lisonbee et al.

Serial No.: 10/663,353

Filed: September 15, 2003

For: COMPOSITIONS INCLUDING DIFFERENT TYPES OF TRANSFER FACTOR, METHODS FOR MAKING THE COMPOSITIONS, AND METHODS OF

TREATMENT USING THE

COMPOSITIONS

Confirmation No.: 1601

Examiner: Unknown

Group Art Unit: 1614

Attorney Docket No.: 2820-5964US

Express Mail Mailing Label Number:	EV348043480US
Date of Deposit with USPS: June 1	0, 2004
Person making Deposit: Christopher	Haughton

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In compliance with the duty to disclose information material to patentability pursuant to 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 or PTO/SB/08 be considered by the Examiner and made of record. Copies of the listed documents are enclosed pursuant to 37 C.F.R. § 1.98(a).

In accordance with 37 C.F.R. § 1.97(g) and (h), filing of this Information Disclosure Statement is not to be construed as a representation that a search has been made or an admission that the information cited herein is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b). Further, no representation is made by Applicants herein that no other possible material information as defined in 37 C.F.R. § 1.56(b) exists.

U.S. Patent Documents

<u>Patentee</u>	Publication Date	U.S. Patent No.
Wilson et al.	03/28/1989	4,816,563
Hennen et al.	10/22/2002	6,468,534 B1
Dopson	04/18/2002	US 2002/0044942 A1

Applicants offer to supply any explanation or discussion of the documents that the Examiner feels is necessary or desirable and which is requested.

This Information Disclosure Statement is believed to be filed before the mailing date of a first Office Action on the merits; therefore, no fee is due.

Respectfully submitted,

Brick G. Power

Registration No. 38,581 Attorney for Applicant(s)

TRASKBRITT P.O. Box 2550

Salt Lake City, Utah 84110-2550

Telephone: 801-532-1922

Date: June 10, 2004

BGP/rmh

Enclosures: Form PTO-1449 or PTO/SB/08

Cited Documents

Document in ProLaw

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Approved for use through 10/31/2002. OMB 0651-0031

	Oraci	uk rapo	WORK REAL CHOIT FACT OF 1995, NO	Persons are required to respond to a con-	ection of information talless it contains a valid Olvid control manuel
Substitut	e for form 1449A/PTO				Complete if Known
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	10/663,353		
		Filing Date	September 15, 2003		
O111			LICINI	First Named Inventor	Lisonbee et al.
				Group Art Unit	1614
(use as many sheets as necessary)		Examiner Name	Unknown		
Sheet	1	of	1	Attorney Docket Number	2820-5964US

	,		U.S. PATENT D	OCUMENTS	
Examiner Initials *	Cite No. ¹	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1	US- 4,816,563	03/28/1989	Wilson et al.	rigures Appear
	1	US- 6,468,534 B1	10/22/2002	Hennen et al.	
	1	US- 2002/0044942 A1	04/18/2002	Dopson	
		US-			
	ĺ	US-			
		US-	_		
		US-			


	FOREIGN PATENT DOCUMENTS						
Examiner Cite Initials* No.1	Cite	Foreign Patent Document		Name of Patentee or	Pages, Columns, Lines,		
	Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T ⁶		
		-					
	 						
	 						


Examiner	Date
Signature	Considered

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.





IMMUNE TRANSFER CIM.

1 Most complete bland of targeted transfer factors for enhanced immune activity > Top selling transfer factor among medical practitioners

immuneTransfer CTM is a scientifically formulated blend of transfer factors derived from chicken lymphocytes and colostrum extracts that contain growth factors and other immune cofactors to provide the body with advanced immune activity. The expanded spectrum of targeted transfer factor molecules found in immune Transfer Con supports. the body in selecting and recognizing a more complex variety of harmful agents that may take advantage of a weakened immune system.

Note: Testing for Lyme, Epstein, Barr Virus (EBV), Human Herpesvirus (HHV6), Cytomegalovirus (CMV), Chlamydia, Babesia and Erlichia is recommended prior to use

this product. Suggested Dally Use: 1 gel cap

30 GEL CAPS

110134, 100 mg (30 day supply) Renal \$159.95 • NOW \$140.00 • SAVE 12% • (DSP \$135.80*)

90 GEL CAPS

gN0138; 100 mg (90 day supply) Retail \$409.00 - NOW \$390.00 - SAVE 5% (DSP \$378.30*)

TRANSFER FACTOR ESSENTIALSTM 1 (is cyanoca arch arbinocalacter

TARGETED TRANSFER FACTORS

TRANSFER FACTOR SYSTEM 100™

Specialized transfer factor molecules enhance the body's immune defense Stimulates immune activity to battle resurgant filmess

i infused with vitamin B-6 to promote healthy energy levels & nerve function Transfer Factor System 1000 contains specialized transfer

factor molecules that support enhanced immune activity and targeted inunune training to battle resurgent limbsses that may take advantage of a weakened immune system. This formula is Infused with vitamin 8-6, a nutrient vital to many bodily functions including converting glycogen to glucose for improved energy, and neuroliansmitter production to support a healthy fiervous system. Note: Testing for Epstein-Barr Virus (EBV) and Cytomegalovirus (CMV) is recommended prior to use of this product.

Suggested Dally Use: 1-3 capsules 4PH171,30 capsules (10 - 30 day supply)

Retail \$29.95 • NOW \$22.95 • SAVE 23% • (DSP \$17.90°)

TRANSFER FACTOR SYSTEM 200™

> Helps re-invigorate immune system activity Contains potent antioxidant and energy producing nutrients Same patented product included in the Hernex^m Lib protocol This proven formula used in the Hernex^M Lab protocol, works synergistically with Coenzyme Q10 and vitamin C to promote optimal immune function and improved energy levels. Both nutrients are potent antioxidants and detoxifiers, while Coenzyme Q10 promotes cellular ATP production for improved energy, and vitamin C supports improved immune cell strength and functioning. Note: Testing for Human Herpesvirus 6 (HHV6), and Cytomegalovirus (CMV) is recommended prior to use of this product.

Suggested Daily Use: 1-3 capsules IPH 172, 30 capsules (10 - 30 day supply) etall \$49.95 • NOW \$43,49 • SAVE 13% • (DSP \$37.84°)



Patented formula includes essential B vitamins Suggested Dally Use: 1-3 capsules #NO147,30 capsules (10 - 30 day supply) Retail \$29.95 • NOW \$23.95 • SAVE 20% • (DSP \$19.88*)

FORMULA 560 (SYSTEM 200 EQUIVALENT)

. Used by health experts at the Chenny Clinic Suggested Daily Use: 3 capsules. #NO146, 30 capsules (10 day supply)

Retail \$49.55 • NOW \$44.49 • SAVE 11% • (DSP \$39.60*)



Click here for information about ImmuneTransfer C TM



ImmuneTransfer C ™ Complex transfer factor for fatigue and more

- ·Top selling transfer factor among alternative medical practitioners
- ·Multi-faceted formula for fatigue and more
- ·One convenient gel cap per day
- ·Transfer Factor is BSE Free
- -30 small gel capsules, 100 mg

Available in one gel cap per day, this specialized transfer factor is a favorite among alternative physicians coping with many of today's common but less understood maladies.

Transfer Factor - the key to immune system memory

Transfer Factor represents one of the most exciting advances in immune system health. Transfer factors are tiny protein molecules, which are produced by immune cells called T-cells. Transfer factor is based on the foundation that key immune information can be transferred from cell to cell. These cells then teach our immune system to recognize specific viruses or bacteria that our bodies may not currently recognize. This is particularly exciting given the therapeutic role transfer factors play in activating and enhancing immunity in individuals suffering from chronic illness.

Highly purified, rigorously tested

Colostrum from healthy, organically fed cows is filtered and purified to provide a mixture of pure transfer factor molecules. In the case of chicken sourced transfer factor, specific transfer factors are derived from healthy chickens and combined with specific growth factors derived from colostrum. Numerous rigorous techniques including further purification and isolation result in pure transfer factor. Every lot produced undergoes



Click here for CUSTOMER
REVIEWS

meticulous testing to ensure that the appropriate and effective levels of each transfer factor are present, before it is encapsulated and bottled.

Also, people who are lactose intolerant or who have allergies need not be concerned about a reaction, since all traces of milk proteins and lactose are removed during the extraction and concentration process.

Note: Testing for Lyme, Epstein - Barr virus (EBV), Human Herpes virus 6 (HHV6), Cytomegalovirus (CMV), Chlamydia, Babesia and Erlichia is recommended prior to use of this product. Regular Price:

\$150.0€

SPECIAL PRICING: Savings: \$19.95

\$140.00

台Add to Secure Cart 1

DSP Program Price: \$135.8(




Important Note About BSE (Mad Cow Disease) & Transfer Factor

Bovine spongiform encephalopathy (BSE) is a progressive brain disorder of cattle that results from infection by an unconventional agent. The agent is a modified form of a normal cell surface component known as prion protein. The pathogenic form of the protein is both less soluble and more resistant to enzyme degradation than the normal form. The prions then build up in the brain and cause damage to nerve cells.

Bovine derived Transfer Factor proteins are not affected by prions. Even if a cow were exposed to BSE, transfer factor protein molecules are a fraction of the size of BSE prions and cannot be infected by them. As a result, the advanced filtering process used to extract the smaller transfer factor molecules eliminates any potential contamination of the product. Transfer Factor is BSE Free. In addition, the cattle used to produce transfer factor are isolated and used exclusively for the processing of transfer factor. Pro Health takes great care to ensure high quality and safety of our supplements as part of our commitment to empower customers to take control of their health.

Ingredients:



- For product questions, click here to chat online with a Product Advisor.
- 30 small gel capsules, 100 mg
- Daily Use: Take 1 gelcap daily or as directed by your physician.
- Shelf Life: 3 years
- Inactive Ingredients: Gelatin, water
- Contains No: Salicylates, Casein, Gluten

Also consider these other complementary products:

ImmuneTransfer C TM-Complex transfer factor for fatigue and more. <u>CFS/FM Energy Formula</u>-Comprehensive fatigue attacking formula.


NADH (Enada)-Favorite for promoting energy & mental clarity.

Related articles and abstracts:

Transfer Factor: Retraining your Immune System

Treating Chronically Ill Patients with Transfer Factor: An Exclusive Interview with Dr. Carol Ann Ryser, M.D.

Transfer Factor-- New Era for Immune Therapy?





Email This Page to a Friend